Method for assessment of kidney function in felines by measurement of ghrelin hormone levels |
|||||||||||||||||||||||||||||||||||||
|
IPC classes for russian patent Method for assessment of kidney function in felines by measurement of ghrelin hormone levels (RU 2403573):
Diagnostic technique for foetal maturity / 2399058
There are determined daily excretion of progesterone metabolite - pregnandiol (Pd), foetal steroids - 16α-hydroxy-ethiocholanolone (16α-OH-Et), 16α-hydroxy-androsterone (16α-OH-An), 16α-hydroxy-dihydroepiandrosterone (16α-OH-DHEA) and oestradiol (Oe) in pregnant women on their 37-42 weeks of pregnancy by capillary gas chromatography. A mature foetus is indicated by the following indices: daily Pd excretion is 150.4-348.3 mcmol/24 hour, 16α-OH-Et - 7.9-16.9 mcmol/24 hour, 16α-OH-An - 6.4-12.6 mkmol/24 hour, 16α-OH-DHEA - 15.4-26.1 mcmol/24 hour, Oe - 24.0-38.7 mcmol/24 hour, while an immature foetus show the indices as follows: daily Pd excretion 80.1-150.2 mcmol/24 hour, 16α-OH-Et - 5.8-7.8 mcmol/24 hour, 16α-OH-An - 4.6-6.3 mcmol/24 hour, 16α-OH-DHEA - 10.2-15.3 mcmol/24 hour, and Oe - 14.5-15.6 mcmol/24 hour, and in a overmature foetus, daily Pd excretion, 16α-OH-Et, 16α-OH-An, 16α-OH-DHEA and Oe are considerably lowered and are less than 50.0 mcmol/24 hour, less than 12.0 mcmol/24 hour, less than 5.8 mcmol/24 hour, less than 4.6 mcmol/24 hour, less than 10.2 mcmol/24 hour, respectively.
Method for prediction of clinical course in disseminated skin melanoma patients / 2399057
Method is implemented by blood analysis for total and free triiodothyronine after the termination of integrated treatment to derive the total to free triiodothyronine ratio, and it is within the range 0.26-0.31, steady state is predicted to be kept in the patients; the ratio within the range 0.19-0.22 ensures to predict the disease generalisation. Technical and economic efficiency of the invention consists in the fact that the derived prognosis factor is an informative laboratory covariant of the favourable or unfavourable development of the pathology.
Method for prediction of effectiveness of neoadjuvant automyelochemotherapy in patients with recurrent breast cancer / 2393484
Prior to begin the therapy, the patient's blood is tested for oestradiol concentration. If the concentration is 18.40 to 29.40 nmol/l, tumour size loss after the neoadjuvant automyelochemotherapy by 67-70% is predicted, that is a partial regress of the tumour, while oestradiol concentration 208.50 to 1541.0 nmol/l enables to predict the tumour size loss by 5-45% that is process stabilisation.
Method for determination severity level of trophological insufficiency in patients with chronic obstructive pulmonary disease / 2390026
Body weight index (BWI) is evaluated; if it is lower than 20 kg/m2, additional analysis is needed to determine the serum leptin concentration. If it is within 16.01±0.64 to 10.15±0.91 ng/ml, the absence of trophological insufficiency is diagnosed, while the values within 5.49±0.46 to 2.26 ng/ml enable to diagnose trophological insufficiency of medium severity, while the values 1.90 to 0.72±0.09 ng/ml indicate severe trophological insufficiency.
Method of forecasting retrocessions of larynx cancer / 2389030
In patients suffering from larynx cancer after surgical oncotomy in the course of dispensary observation levels of androsteron and estradiol in 24-hour collection urine are examined and their ratio to each other are determined. At ratio level more than 3 emergence of disease retrocession or metastasis in the near future is forecasted. At ratio level lower than 3 a long-lasting recurrence-free period is forecasted.
 Diagnostic technique for desynchronosis of hypophysial thyroid system in patients with severe bronchial asthma, previously not taking glucocorticoid therapy / 2382366
Diagnostic technique for desynchronosis of hypophysial thyroid system in the patients with severe bronchial asthma refers to medicine. Substance consists that blood of the patients is radioimmunoassayed for concentration of TSH, T3, T4 hormones. The obtained data are processed to draw a graphic curve of circadian rhythm for each hormone that provides a basis to determine individual acrophase and batiphase time. The acrophase (confidence interval) TSH development biorhythm 9 h 11 min (confidential interval 4 h 57 min to 13 h 26 min), T3 hormone - 15 h 01 min (confidential interval 8 h 05 min to 21 h 57 min) T4 hormone - 16 h 34 min (confidential interval 8 h 55 min to 24 h 13 min), and batiphase of circadian TSH secretion rhythm 21 h to 22 h, T3 - 2 h to 4 h, T4 4 h to 5 h ensure to diagnose apparent desynchronosis of hypophysial thyroid system.
Method for predicting depressive behaviour in aged primate, rates of aging and development of stress-dependent pathological changes / 2377570
Invention refers to medicine and veterinary science and can be used for predicting depressive behaviour of an aged primate, rates of ageing and development of stress-dependent pathological changes. According to the claimed invention, an aged primate is examined for psychoemotional reaction on soft and acute psychoemotional stress effect, molar concentration ratio of cortisol and dehydroepiandrosterone sulphate in peripheral blood plasma and percentage concentration of cortisol in peripheral blood plasma in the evening (20 o'clock 45 minutes - 21 o'clock 15 minutes) to concentration of cortisol in peripheral blood plasma in the morning (8 o'clock 45 minutes - 9 o'clock 15 minutes) to predict depressive behaviour in the aged primate with accelerated rates of ageing and development of stress-dependent pathological changes in depressive reaction on soft and acute psychoemotional stress effect, if molar concentration ratio of cortisol and dehydroepiandrosterone sulphate in peripheral blood plasma is not less than 4.3, and concentration of cortisol in peripheral blood plasma in the evening to concentration of cortisol in peripheral blood plasma in the morning is not less than 66%.
Method of estimating efficiency of neoadjuvant autohemochemotherapy in patients suffering from carcinoma of cervival stump / 2375063
Invention concerns medicine, namely oncology and can be used in estimation of clinical effectiveness factors in treatment of carcinoma of cervical stump. Daily urine is analysed for estradiol content and if decreased after treatment from initial level within 8.44-12.85 nmol/days, positive antineoplastic effect of treatment is stated, and if urine estradiol content is maintained in the treated patients within 8.81-11.38 nmol/days, the absence of antineoplastic effect is stated. The obtained results allow considering dynamics of estradiol content in daily urine of the patients suffering from carcinoma of cervical stump prior to AHCT as an additional laboratory test to estimate efficiency of presented pharmacotherapy. Observed positive clinical effect is confirmed by higher operability and improved life quality of the patients.
Method of determining effeciency of larynx cancer treatment / 2375003
Invention relates to medicine, namely to oncology and can be applied in presence of locally advanced process. In daily urine of patients before treatment tetrahydro-11-desoxycortisol is determined. If its level before treatment does not exceed 2 mcmol/day relapse-free period is forecasted during 2 and more years; initial level of fraction over 2 mcmol/day indicates about disease relapse or metastases during first year after treatment.
Way of forecasting of restoration of menstrual function at patients with nervous anorexia / 2363002
Invention concerns medicine, namely to gynecology, and can be used at treatment of patients with amenorrhea caused by nervous anorexia. Level of leptin is defined in blood serum using enzyme immunoassay method for realisation of the way of forecasting of restoration of menstrual function at patients with a nervous anorexia. Then an index of mass of a body (BMI) and a parity leptin/BMI is counted. In case the parity leptin/BMI makes 0.8 and more - normalisation of menstrual function is prognosticated.
 Double hybrid system based on gene silencing by transcriptional interference / 2403287
Invention relates to biotechnology. The invention describes a yeast cell which contains an interference DNA construct. The construct comprises: a reporter gene under control of a first promoter; one or more in induced promoters called interference promoters selected and fixed in such a way that their activation induces transcriptional interference of the first promoter leading to a detectable decrease in expression of the reporter gene. The cell expresses: a first chimeric protein (Y-AD) formed by a transcription activation domain (AD) fused with a protein Y capable of interacting with at least a partner protein X; a second chimeric protein (X-DBD) formed by a first DNA-binding domain (DBD) fused with a second domain formed by protein X capable of interacting with protein Y, wherein the interaction of the two chimeric proteins X-DBD and Y-AD leads to formation of a functional transcription factor which activates the interference promoter(s). The invention discloses a method of intensifying a compound which inhibits interaction of the first protein X with the second protein Y.
Method of estimating local inflammation activity in case of background neck of uterus diseases and device for removal of native material from neck of uterus surface / 2402779
In estimation of local inflammation activity in case of background diseases of neck of uterus sampling of analysed biomaterial is performed by bringing of device for native material removal to external neck of uterus fauces. Said device has elongated holder in form of rod with length, exceeding length of vagina. From distal side of rod, at angle to it, located is operation element in form of roller. Proximal end of rod serves as manipulator-handle. Sampled material is placed until complete submergence into tightly closable test tube, filled with 1.0 ml of 0.155 M solution of sodium chloride. Mixture is centrifuged for 10 minutes. Obtained materials are analysed by method of solid phase ELISA analysis on boards by means of set of reagents "Vector-Best". Concentration of cytokine of interleukin-6 in analysed samples is determined spectrophotometrically. If value is higher than 50 pg/ml to 92 pg/ml, conclusion about presence of chronic inflammation process is made. If value is higher than 92 pg/ml, conclusion about active course of inflammatory process and expressed immune response is made.
 Method of screening phage display library / 2402777
Invention can be used for obtaining diagnostic and/or therapeutic agents, in particular antibodies, which specifically interact with proteins of cell surface of target cells. Claimed is method of screening phage display library and including it method of isolation of library element, which is specific partner of binding of target cell surface protein, and method of isolation of unknown cell surface protein, specifically interacting with library element. Method of screening phage display library according to invention includes contact of said library with cells of interest with further separation of cells, which bound with one or several elements of expression library, from non-bound elements by separation through organic phase, and differs by introduction of additional stage, which consists in carrying out before said separation of at least one stage of material washing, and ensures essential increase of method efficiency.
Method of treating atopic dermatitis in children with diagnosed cytomegalovirus infection / 2402776
Method includes application of complex basic and local drug therapy, as complex base drug therapy, used are Farmvir, Viferone-1, Zyrtec, Selzink, sorbent Lactofiltrim, enzyme Creon 10000 U, as local therapy used are Advantan-cream or ointment, Bepanthen or D-panthenol, or Topicream, moisturizing creams or oils, Farmvir being administered in dose 10-15 mg/kg of body weight, 7-day course, Viferone-1-150000 U - one suppository two times per day, 10-day course, after that one suppository every second day, 20-day course, Zyrtec - 2.5-5.0 mg/kg of body weight per day, one month course, Selzink (7 mg) - 0.5 tablet per one intake one time per day, two month course, Lactofiltrum - one tablet three times per day, 10-day course, Creon 10000 U, 7-10-day course, Advantan - one time per day until exacerbation of skin process is stopped, Bepanthen or D-panthenol, or Topicream - three-four week course, moisturising creams or oils for a long period of time.
Method of diagnosing early manifest congenital syphilis / 2402775
For diagnostics of early manifest congenital syphilis values of cellular, humoral link of immunity and phagocytosis in acute period of disease are determined. If values of relative number of CD8 + - subpopulation of T-lymphocytes are over 20.0% and phagocytic number of neutrophils is over 4.2 units with respect to control group, and if values of IRI (CD4 +/CD8 +) is lower than 2.9 and relative content of CD95 + - lymphocytes is lower than 19.6%, than in control group, early manifest congenital syphilis is diagnosed.
 Recombinant plasmid pd4spgbd, escherichia coli strain - recombinant protein d4-gbd producer, recombinant protein d4-gbd and method for making thereof, method for studying protein d4-gbd fixation to serum antibodies, method for making specific protein d4-gbd antibodies / 2401305
Invention represents plasmid DNA pD4spGBD enabling the expression of a recombinant antigen - protein LigA L. interrogans domain 4 in chimeric protein D4-GBD and 1,3-β-glucan-binding domain (GBD), and a method for making a based subunit engineered leptospirosis vaccine.
 Recombinant plasmid pd5spgbd, escherichia coli strain - recombinant protein d5-gbd producer, recombinant protein d5-gbd and method for making thereof, method for studying protein d5-gbd fixation to serum antibodies, method for making specific protein d5-gbd antibodies / 2401304
Invention represents plasmid DNA pD5spGBD enabling the expression of a recombinant antigen - protein LigA L. interrogans domain 5 in chimeric protein D5-GBD and 1,3-β-glucan-binding domain (GBD), and a method for making a based subunit engineered leptospirosis vaccine.
Method of diagnosing morphological types of uterine leiomyoma / 2400757
Immunological analysis and general blood test are carried out. In blood TNF-α, absolute content of CD4+lymphocytes, relative content of T-cytotoxic lymphocytes CD8+, results of spontaneous NBT-test are determined, in blood serum - general complementary activity, and Y index is calculated by formula. If Y value is less than 4.6, non-proliferative version of uterine myoma is predicted, if Y is higher than 6.8, proliferating version of uterine myoma is predicted; if Y is from 4.6 to 6.8 prognosis is indefinite, it is necessary to apply method of descriptive statistics (use of qualitative anamnestic and clinical criteria).
 Method of diagnosing hypervirus eye diseases / 2400756
In tear fluid by means of immunoblotting presence of antibodies IgM and IgG to specific cytomegalovirus antigens is determined.
 Method of diagnosing intrauterine infection in mothers with urogenital chlamydiosis / 2400755
Invention relates to field of medicine, namely to obstetrics and neonatology. In order to diagnose intrauterine chlamydiosis infection in newborns morphological analysis of placenta tissues, obtained after delivery, is carried out. Semi-thin cuts of placenta are analysed, non-specific changes, characteristic of infectious placentitis, are detected in them. After that on slides with material applied are antibodies, peroxides is revealed by means of diaminobenzidine, put under cover glass, analysed in light microscope. If complexes peroxides-Chlamydia is present, Chlamydia infection in newborn is diagnosed.
 Method of ihtioviruses isolation from clinic material of fish for diagnostic and monitoring research / 2402774
Particles of covering tissues, which are applied for virus isolation, after preliminary washing in medium with increased content of antibiotics, are placed in bottles with nutrient medium - medium EMEM or medium 199 with 2% of cow foetus blood serum and 200 U/ml of penicillin, 200 mcg/ml of streptomycin and 25 mcg/ml of nystatin. Incubation is carried out during 3-5 days at optimal temperature for virus reproduction and constant swing on shaker (50 swings per min.). After that virus separation from tissue is carried out.
|
FIELD: veterinary science. SUBSTANCE: method for assessment of kidney function in felines includes determination of observed level of ghrelin in tissue or biofluid of feline and establishment of direct dependence of observed level of ghrelin on kidney function by comparison of observed level of ghrelin with reference level of ghrelin that characterises normal kidney function. Method for diagnostics of kidney disease in felines includes detection of observed level of ghrelin in tissue or biofluid of feline and comparison of observed ghrelin level with referent level of ghrelin, which characterises normal kidney function, where observed level lower than reference level indicates kidney disease or predisposition to it. Method for detection of kidney disease beginning in felines includes monitoring level of ghrelin in tissue or biofluid of feline for a certain period of time; where beginning is identified, if at any moment of time level of ghrelin decreases compared to initial level that characterises healthy kidney function. Diagnostics set includes (a) one or more test materials to detect observed levels of ghrelin in tissue or biofluid of feline; and (b) one or more user-available mediums bearing the following information: (i) reference level of ghrelin that corresponds to a specific feline; and (ii) algorithm of direct dependence of observed ghrelin level relative to reference level on kidney function or reverse dependence of observed ghrelin level relative to reference level on availability of kidney disease or predisposition to kidney disease. EFFECT: early diagnostics of kidney function abnormalities in felines. 20 cl, 1 tbl, 1 ex
The LEVEL of TECHNOLOGY The technical field to which the invention relates The present invention relates to methods of assessment of renal function in cats and how to diagnose kidney disease in cats. The invention also relates to kits and means of communication used in the implementation of the methods of the invention. Description of the prior art Kidney disease in cats are the second main cause of cat deaths. Possible causes of kidney disease in cats include congenital disorders (cat, born with one kidney, or renal dysfunction), renal infection (derived from untreated obstruction of the urethra), reduced blood flow in the renal artery (caused, for example, diabetes, renal obstruction, tumors or arterial collapse), toxic chemicals, glomerulonephritis, interstitial nephritis, infection with virus leukemia cats, infectious peritonitis in cats, high blood pressure and kidney tumors. Because the backup volume of the kidney is large, kidney disease can progress undetected for a long time, and by the time symptoms of the disease become apparent, from 60% to 75% of the renal mass may be lost. Despite the fact that kidney disease in Kosh is to are progressive and fatal early diagnosis may allow you to deal effectively with the disease for some period of time. Thus, there is a need to develop new ways to assess kidney function and how to diagnose kidney disease in cats. Ghrelin is a peptide hormone produced by endocrine cells in the placenta, kidney, pituitary and hypothalamus and epithelial cells lining the fundus of the stomach. The original synthesized as preprohormone, ghrelin is the product of the proteolysis of the peptide consisting of 28 amino acids. Ghrelin stimulates growth hormone secretion and regulates energy balance. In rodents and humans ghrelin increases hunger through the activation of hypothalamic centers saturation. Increasing regulation of ghrelin secretion occurs under conditions of negative energy balance, and decreasing regulation occurs under conditions of positive energy balance. It is reported that in humans, dogs, and rodents levels of ghrelin in the blood increased with decreasing renal function. This is not unexpected, since the decrease of kidney function indicates low energy and, thus, the need for increased food consumption. Increased levels of ghrelin in the blood of these mammal species effect on appetite and in turn increase the AET meal. The INVENTION It was found that in cats the levels of ghrelin in serum are in direct or inverse connection with certain indicators of kidney function, such as urea nitrogen, blood (BUN). Accordingly, we propose a method of estimating renal function in cats, including the determination of ghrelin in the tissues or bioliquids in cats and direct dependence of the level of ghrelin on renal function. The invention also provides a method of diagnosing kidney disease in cats, including the identification of the observed ghrelin levels in tissues or bioliquids cats and comparing the observed level of ghrelin with referential content of ghrelin, the corresponding normal kidney function, where the observed level below the reference level is evidence of kidney disease, or the predisposition towards it. The invention also provides a method of determining the occurrence of kidney disease in cats, including monitoring of ghrelin levels in tissue or bioliquids cats for some period of time, where the occurrence of the disease state in the case, if at any point in time is detected decreased levels of ghrelin compared with the initial level, the corresponding normal renal function. The invention also provides a method of selecting the mode for cats, including(a) determining the level of ghrelin in the tissue or bioliquids cats; (b) assessment of renal function on the basis of its direct relation with the level of ghrelin and (c) selection mode, the function of the kidneys. The invention also provides a method of evaluating the effectiveness of positive effects on reduced kidney function in cats, including (a) determining the initial level of ghrelin in the tissue or bioliquids cats to start mode; (b) monitoring the observed ghrelin levels at least once after the start of the mode, and (c) comparing the observed level from the initial level, where the preservation or enhancement of the observed level relative to the initial level is a sign of the effectiveness of the regime. Also available diagnostic kit comprising (a) one or more test materials to determine the observed levels of ghrelin in the tissue or bioliquids cats and (b) one or more user-accessible environments, supporting information that includes (i) reference ghrelin levels are appropriate for cats, and (ii) algorithm, which uses a direct relationship observed ghrelin levels relative to the reference level of kidney function, or which use the inverse relationship observed ghrelin levels relative to the reference level in the case of kidney disease, or the predisposition towards it. Also available is estva for transmitted information concerning the dependence of the level of ghrelin on renal function in cats comprising one or more commodity label, leaflet insert in the packaging, brochure, prospectus, leaflet, public statement, tape recording, tape, video, DVD, CD-ROM, readable by a computer, an integrated circuit card or disk, storage device, computer or web page. DETAILED description of the INVENTION Cats, like other animals, reduction in kidney function identified by elevated levels of BUN, creatinine and BUN to creatinine. Currently, found that domestic cats elevated levels of BUN or increased the ratio of BUN to creatinine corresponds to low levels of ghrelin. Because the BUN is a known indicator of decreased kidney function, it can be concluded that the levels of ghrelin directly related to renal function in cats. This conclusion is unexpected and contrary to the assumptions based on observations of the levels of ghrelin in other species of animals. The methods of the invention are suitable for cats, which include, for example, domestic cats. Other animals belonging to the cat family, such as lions, tigers, jaguars and other wild and domestic cats here also refer to the concept of "cat". The kidneys have many functions, including filtering waste products of the body (mainly urine and creatinine), regulation is their levels of electrolytes in serum (potassium, calcium, phosphorus and sodium), production of erythropoietin (which stimulates the bone marrow to produce red blood cells), production of renin (an enzyme that controls blood pressure and the production and concentration of urea. Weakened kidney function may indicate chronic or acute kidney disease. Acute kidney disease include, but are not limited to, obstruction of the urinary tract, infectious disease, injury and poisoning. Chronic kidney disease include, but are not limited to, chronic renal failure, chronic tubulointerstitial nephritis, glomerulonephritis, pyelonephritis, amyloidosis, hydronephrosis, lymphoma kidney, cystic kidney disease, kidney aplasia, hypoplasia of kidney dysplasia of kidneys and kidney disease due to congenital diseases. Used the term "kidney disease" includes any kidney dysfunction or disorder regardless recognize whether it is usually as a disease or syndrome. The method of the invention for assessing kidney function in cats includes determining the level of ghrelin in the tissue or bioliquids cats and directly binds ghrelin levels with renal function. Used stage direct relationship is characterized as identification of the status of the kidney, consistent with the level of ghrelin by the sing the direct correlation between ghrelin levels and renal function. For example, high levels of ghrelin may indicate normal kidney function, while low levels of ghrelin may indicate decreased kidney function. To determine the levels of ghrelin can be used any fabric or biojidkosti. Usually are more desirable tissue or a liquid that can be obtained with minimum invasion. For example, Biebrza is a tissue sample or bioliquids used to determine the levels of ghrelin, which is produced from a living animal. Alternatively, the levels of ghrelin can be determined in situ without the necessity of obtaining Biebrza. The tissue may include, but are not limited to, bone, muscle, kidney, liver and so on. Bioliquids as illustrations include whole blood, blood serum, blood plasma, cerebrospinal fluid, crevicular fluid, breast milk, urine, lymphatic fluid, intramuscular fluid, nasal secretions and saliva. Bioprotec can be assembled, for example, in place of medical care, i.e. the place where the animal can be examined by a specialist medical care (for example, a veterinarian, a veterinary technician, and so forth) for evaluation and diagnosis. Alternatively, bioprotec can be taken in the house where the animal lives on a farm, Kona is šnē, in a kennel or cattery, where the animal is contained. When bioprotec taken once the selection it is usually produced on an empty stomach, for example in the morning (before eating) time. However, bioprotec can be obtained at any stage of the cycle of feeding cats, for example in the morning or at a suitable time after eating (afternoon). When bioprotec taken repeatedly, it is usually taken at the appropriate stage of the cycle of feeding, and it is most convenient to do on an empty stomach. However, bioprotec can be obtained at different times in the cycle of feeding, including at least one morning time and at least one afternoon point in time. Ghrelin levels from Biebrza obtained from cats, can be defined locally, for example at the point of medical care, which produces a selection of Biebrza. This set can be optionally used to determine the level of ghrelin. Alternatively, bioprotec can be sent in a secondary institution. Used herein, the term "secondary institution" refers to the laboratory, such as commercial laboratories for medical analyses, where evaluate clinical samples, which may be outside (i.e. in another place) to provide medical assistance. In some variant of the x implement one or both of the stage of determining the level of ghrelin and use direct proportion to the level of ghrelin from kidney functions are carried out either in the health-care or in a secondary institution. The levels of ghrelin can be determined using known in the art test systems. The analysis may include any commercially available or are not commercially available test system. Usually analysis method is chosen based on the type of fabric or bioliquids, which are going to determine the level of ghrelin. For example, to determine the level of ghrelin in serum can be used a commercially available test kit for monoclonal immunological analysis using monoclonal antibodies that react with one or more epitopes of the molecule ghrelin. In some embodiments, the implementation levels of ghrelin determined using one or more methods enzyme-linked immunosorbent assay, ELISA analysis with the enzyme label immunofluorescence analysis, radioimmunoassay, Western blot analysis, biochemical analysis, enzyme analysis or colorimetric analysis. The variety of labels and conjugation methods known to experts in this field, and they can be used in various analyses. Ghrelin levels in the sample can be unadjusted or adjusted for body weight cats. The unadjusted level can be expressed in concentration units mass/volume, such as mg/l, µg/l or ng/l, or in units of melanocortin, such as µmol/l, nanomoles/l or picomol/l Adjusted level can be expressed in the same units, but with body mass (MT) as a divider, for example mg/l/kg MT, picomol/l/kg MT and so on. The invention also provides a method of diagnosing kidney disease in cats, including the identification of the observed ghrelin levels in tissue or bioliquids cats and comparing the observed level of ghrelin with reference ghrelin levels, characterizing the normal function of the kidneys, where the observed level is lower than the reference level indicates kidney disease or the predisposition towards it. Used herein, the term "observed ghrelin levels" means the levels of ghrelin, defined in fabric bioliquids examined cats. Reference ghrelin levels are usually characterized by normal kidney function. The reference level can be set from one or more biological samples obtained from one or more cats with normal renal function. Usually the reference levels set for cats of the same breed or breed type. In addition, it is desirable that the reference levels established for cats specific age groups and/or for each sex. Reference ghrelin levels can also be set from the publicly available documentary data, such as values of g is yellin in the literature, or rules on the basis of documentary data. In some embodiments, the reference implementation ghrelin levels can be obtained from the data available for professionals, establishing the diagnosis. In some embodiments, the implementation of the observed levels of ghrelin define at first the cat, and the reference levels of ghrelin determine the second cat, where the second cat has normal renal function. In other embodiments, implementation of the observed and reference levels of ghrelin define one and the same cat at different points in time. For example, in the first moment of time may be set to an initial or reference levels of ghrelin. The levels of ghrelin, defined in one or more subsequent points in time, can be considered as the observed levels of ghrelin. The observed and reference levels of ghrelin determined biebrach received in time, which usually differ, at least about 4 hours, for example at least about 8 hours, at least about 12 hours, at least about 24 hours, at least about 3 days, at least about 7 days, or at least about 1 month. In some embodiments, the implementation of the observed level of GRE is in below than the reference level indicates kidney disease. In other embodiments, implementation of the observed ghrelin levels are lower than the reference level indicates a predisposition to kidney disease. As an example, the observed levels of ghrelin, at least about 10%, at least about 15%, at least about 20%, at least about 25% or at least about 30% lower than the reference level of ghrelin, is evidence of kidney disease or predisposition thereto. In General is a big difference between the reference level and the observed level of evidence of a greater depression of renal function or a more serious condition kidney disease. Kidney disease usually progresses over time, first being invisible to the Trustee of the cats and/or not being treated. By that time, when kidney disease is outwardly expressed, kidney function is already severely weakened. However, if the kidney disease is defined at the beginning or the cat identified as having a predisposition to kidney disease, the animal can be helped to minimize the effect of the disease. The invention provides a method of determining the start of kidney disease in cats, including monitoring of ghrelin levels in tissue or bioliquids cats for some period of time the Yeni, where it begins, determine if at any point in time ghrelin levels are reduced in comparison with the initial level typical for healthy kidney function. According to this method, the levels of ghrelin in cats constantly watching for some period of time, and the beginning of kidney disease to determine if at any time during this period, the level of ghrelin decreases relative to the initial level of ghrelin. The decrease may be statistically significant, but this is optional. Monitoring the level of ghrelin may be carried out in any convenient interval such as approximately every hour, twice a day, every day, twice a week, weekly, monthly, every two months, twice a year or annually. In addition, the invention provides a method of selecting the mode for cats, including (a) determining the level of ghrelin in the tissue or bioliquids cats; (b) assessment of kidney function using its direct link with the level of ghrelin and (c) selects the function of the kidneys. One variant of implementation optionally includes the additional step (d) instructing the Trustee cats about the selected mode. This option may not be considered as a method of prescriptions mode for a cat. The appropriate mode of kidney function, may be selected by the Trustee cats on cos the ve information transmitted by any appropriate means of communication, or may be prescribed or proposed by the expert in the field of health. The mode may include nutritional or pharmaceutical effects, or both. Dietary exposure may be a way to provide compositions for feeding cats. The composition has a content of nutrients, the corresponding estimated kidney function. As an example, such a composition may be nutritional composition, such as a food composition, additive, food or a toy, it should be noted that some, but not all, supplements, treats and toys are themselves food compositions. The food composition can be, for example, swallowed by animals or introduced animal by feeding. A suitable composition is the usual composition, which dietologicheskie selected for feeding cats with healthy or weakened kidney function. The food composition may be specially adapted to the special nutritional needs of cats of specific breeds, ages, gender and so on. The composition can be supplied with words or without. Pharmaceutical effects, appropriate renal function may include the introduction of the cat, at least one kidney of the medicinal product in accordance with t repitions effective regime. For example, such a drug may be selected from ACE inhibitors, inhibitors of endothelin, inhibiting azapeptide, calcium channel blockers, H2 antagonists of the receptor, inhibitors of the proton pump, protectors, antiemetics, androgens, erythropoietin, phosphate binders, calcitriol and their combinations. The mode can be continued with appropriate frequency or over a period of time, if necessary or consistent with the function of kidneys, either healthy or weakened. As an example, the mode may persist for at least about 1 month, at least about 2 months, at least about 6 months, at least about 1 year, or within some other time specified as necessary or appropriate, for example, a veterinarian or other health care specialist. The invention also provides a method of assessing the effectiveness of treatment of kidney function in cats, including (a) establishing an initial level of ghrelin in the tissue or bioliquids cats to start mode; (b) monitoring the observed levels of ghrelin, at least at one point of time after the start of the mode, and (c) comparing the observed level from the initial level, where the preservation or increase of the observed level relative to the initial the level characterizes the efficiency of the mode. The initial level of ghrelin determine before you start using a particular mode for a cat. Then, as described above, ghrelin levels are monitored at one or more points in time following the start of the mode. The observed level (levels) ghrelin relative to the initial level of ghrelin may individually or in the form of a set of data to characterize the effectiveness of the regime in the treatment of kidney function. For example, the preservation or enhancement of the observed ghrelin levels relative to the initial level characterizes the efficiency of the mode. It is also proposed diagnostic kit comprising (a) one or more test materials to determine the observed levels of ghrelin in Biebrza received the cat; and (b) one or more user-accessible environments, supporting information that includes (i) reference ghrelin levels corresponding to the cat; and (ii) an algorithm that establishes a direct dependence of the observed ghrelin levels relative to the reference level of kidney function or inverse relationship observed ghrelin levels relative to the reference level on the presence of kidney disease or predisposition thereto. As mentioned in the above embodiments, implementation, observed ghrelin levels are lower than the reference level, characterizes the illness is the W kidney disease, or predisposition thereto. "Available-for-user environment include all environments, such as paper, disk, memory chip, card, computer, or network, of which can be extracted instruction information, the algorithm and/or contained or stored data. The algorithm typically is a software-implemented algorithm. The set is not necessarily a set, which does not require additional equipment, i.e. does not require laboratory equipment. The kit optionally further includes a device for selecting Biebrza. In the set can be used one or more of the many methods of analysis for determining the level of ghrelin, including the above analysis methods. For calibration in the quantitative determination of the level of ghrelin in Biebrza can be included and used standards and standard additions. In some embodiments implement one or more test materials may include one or more reagents. In other embodiments implement one or more test materials kit may include at least one antibody such as a polyclonal or monoclonal antibody against ghrelin. The antibody can be mobilisierung on solid media. For example, an ELISA may be used to determine the level of ghrelin in the sample. ELISA may involve the binding of antibodies to TBE the house media such as a polymer. The sample, including ghrelin, may be introduced and subjected to interaction with the antibody, and therefore able to be carried out, the process of generating signal (for example, a chromogenic signal) to produce an optically detectable signal. In one embodiment, the kit comprises a first antibody that specifically binds with ghrelin in the sample, and a second antibody that specifically binds with the received complex of the first antibody with ghrelin. The second antibody can be mobilisierung on solid media. For example, when binding of the second antibody to the complex of the first antibody/ghrelin second antibody initiates the reaction and, for example, lead to detectivemisa color change. Diagnostic kit may optionally include a means of transmitting information or instructions regarding (a) the evaluation of renal function and diagnosis of kidney disease in cats or (b) offered or prescribed mode of the function or kidney disease, as described above. Means may be affixed to the packaging or attached to the package containing the other elements of the set. Can be used with any appropriate transmission medium, such as a document, such as a label, brochure, advertisement or flyer insert in the package, to read what newterm digital or optical medium, such as a floppy disk, CD, audio presentation, for example, tape recording or CD, or video, for example, on tape for video or DVD. Transmission media may include additional information that is located elsewhere, for example on the Internet site. In yet another additional embodiment, the means for transmitting information concerning the dependence of renal function on the level of ghrelin in cats, including one or more label, leaflet-leaflet, brochure, prospectus, advertisement, public announcement, tape recording, tape, video, DVD, CD-ROM, readable by a computer, an integrated circuit card or disk, storage device, computer or web page. The invention is not limited to described a particular methodology, protocols, and reagents, as they may vary. In addition, the terminology used is used only for the purposes of the description of specific options for implementation, and it is assumed that it does not restrict the scope of the present invention. Used in the claims, the singular number include the objects and the plural, unless the content clearly indicates otherwise. Similarly, the words "include," "includes" and "including" should be understood as the inclusion of something, not the exception. If not defined otherwise,all the technical and scientific terms, and any abbreviations have the same meanings, as they understand any ordinary specialist in this area, to which the invention relates. Although any methods and materials similar or equivalent to those described can be used in the implementation of the present invention, in the description of the invention describes the preferred methods, devices, and materials. Everything mentioned in the description of the patents, patent applications and publications cited by reference to the extent permitted by law for purposes of this description and disclosure of the compounds, methods, techniques, methods, technologies, products, and other disclosed here are compositions and methods that can be used with the present invention. However, nothing here should be interpreted as a recognition that the invention unauthorized opposes this description of the invention with an earlier priority. EXAMPLE The invention can be further illustrated by the following examples of its preferred embodiments, although it should be borne in mind that these examples are included only for purposes of illustration, it is assumed that they do not limit the scope of the invention unless specifically stated otherwise. An example is presented in the form of research, illustrating the fact that the levels of ghrelin relative to the reference level of ghrelin can svidetel the part about kidneys and kidney disease or the predisposition towards it. Before the study, 40 cats fed the same diet containing sufficient amounts of nutrients to meet the minimum nutrient requirement. Cats do not show signs of renal disease. In the beginning of the study cats divided into four groups of 10 cats each and every group prescribe one of four commercially available cat foods. Cats enter the prescribed food to them daily for 30 days. Cats provide fresh food daily and provide access to food for 20 hours. The collection of blood and urine tests carried out in zero-day and 30 day. The levels of ghrelin and BUN determined in serum and define microalbuminuria in urine using traditional methods. The microalbuminuria is assessed through a set of Heska ERD. To determine the levels of ghrelin using ELISA. Creatinine and BUN define conventional chemical screening analysis. The following table lists the metabolites in the blood and urine density, measured at 30 days.
Each of the four feed contains different concentrations of various nutrients and leads to different results from the point of view of the kidney, as shown, at least with BUN levels. The results show that low levels of ghrelin wonder associated with high SD is vname BUN, which, as you know, are an indicator of impaired renal function. In the description have been disclosed typical preferred embodiments of, and although specific terms, they are used only in the ordinary and descriptive sense and not for purposes of limitation, the amount of an invention shall be determined by the claims. Obviously, many modifications and variations of the invention are possible in light of the above descriptions. Therefore, it should be borne in mind that within the scope of the attached patent claims the invention may be implemented otherwise than specifically described. 1. Method of assessment of kidney function in cats, including the identification of the observed ghrelin levels in tissue or bioliquids cats and direct determination of dependence of the observed levels of ghrelin from the kidney function by comparing the observed level of ghrelin with reference ghrelin levels that characterize normal renal function. 2. The method according to claim 1, in which a cat is a house cat. 3. The method according to claim 1, in which the fabric or biojidkosti includes bioprotec taken from cat. 4. The method according to claim 3, in which bioprotec includes whole blood, blood plasma or serum. 5. The method according to claim 3, in which bioprotec get when a cat is hungry state (fasting). 6. The method according to P3, in which ghrelin levels in Biebrza determined using one or more methods enzyme-linked immunosorbent assay, ELISA analysis with the enzyme label immunofluorescence analysis, radioimmunoassay, Western blot analysis, biochemical analysis, enzyme analysis or colorimetric analysis. 7. The way to diagnose kidney disease in cats, including the identification of the observed ghrelin levels in tissue or bioliquids cats and comparing the observed level of ghrelin with reference ghrelin levels, characterizing the normal function of the kidneys, where the observed level is lower than the reference level, is evidence of kidney disease, or the predisposition towards it. 8. The method according to claim 7, in which the reference level of ghrelin is the norm, based on documentary data. 9. The method according to claim 7, in which the observed levels of ghrelin define at first the cat, and the reference levels of ghrelin determine the second cat with normal renal function. 10. The method according to claim 7, in which the observed levels of ghrelin, at least about 10% lower than the reference level of ghrelin, is evidence of kidney disease, or the predisposition towards it. 11. The method according to claim 7, in which the observed and reference levels of ghrelin define one and the same cats in various who's time. 12. The method according to claim 11, in which the observed and reference levels of ghrelin determine the points in time that are different, at least about 4 hours 13. The method according to claim 11, in which the observed and reference levels of ghrelin determine the points in time that are different, at least about 7 days. 14. The method of determining the beginning of kidney disease in cats, including monitoring of ghrelin levels in tissue or bioliquids cats for some period of time, where you start determines if at any time there decrease ghrelin levels compared with the initial level, characterizing healthy kidney function. 15. The method according to 14, in which the reduction is at least about 10% relative to the initial level. 16. The method of selecting the mode for cats, including 17. The method according to clause 16, which includes nutritional impact or pharmaceutical effects, or both. 18. A method of evaluating the effectiveness of providing a positive impact on renal function in cats, including 19. Diagnostic set, includes 20. Diagnostic kit according to claim 19 which further includes means of transmitting information or instructions regarding (a) the evaluation of renal function or diagnosis of kidney disease in cats or (b) offered or prescribed mode of the function or kidney disease.
|
||||||||||||||||||||||||||||||||||||